
CRXT
Healthcare · Pharmaceuticals · $2.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · +25.0% over 90 days · 30-day revisions 3 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 18, 2022 | After the close | -0.29 | -0.24 | +17.2% |
| May 16, 2022 | After the close | -0.40 | -0.61 | -52.5% |
| Mar 30, 2022 | After the close | -0.68 | -0.19 | +72.1% |
| Nov 18, 2021 | After the close | -0.81 | -0.26 | +67.9% |
| Jul 23, 2021 | After the close | -6.26 | -1.98 | +68.4% |
| May 6, 2021 | Time not confirmed | — | -0.65 | — |
| Sep 3, 2020 | Time not confirmed | — | 0.00 | — |
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and…